Vergent Bioscience

Vergent Bioscience

Biotechnology, 5810 W 78th St, Minneapolis, Minnesota, 55439, United States, 1-10 Employees

vergentbio.com

  • twitter
  • LinkedIn

phone no Phone Number: +18*********

Who is VERGENT BIOSCIENCE

Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by significantly improv...

Read More

map
  • 5810 W 78th St, Minneapolis, Minnesota, 55439, United States Headquarters: 5810 W 78th St, Minneapolis, Minnesota, 55439, United States
  • 2016 Date Founded: 2016
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from VERGENT BIOSCIENCE

Vergent Bioscience Org Chart and Mapping

Employees

Eric Bensen

VP of Research and Development

Maggie Neptune

Vice President, Clinical Operations

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Vergent Bioscience

Answer: Vergent Bioscience's headquarters are located at 5810 W 78th St, Minneapolis, Minnesota, 55439, United States

Answer: Vergent Bioscience's phone number is +18*********

Answer: Vergent Bioscience's official website is https://vergentbio.com

Answer: Vergent Bioscience's revenue is $1 Million to $5 Million

Answer: Vergent Bioscience's SIC: 2834

Answer: Vergent Bioscience has 1-10 employees

Answer: Vergent Bioscience is in Biotechnology

Answer: Vergent Bioscience contact info: Phone number: +18********* Website: https://vergentbio.com

Answer: Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by significantly improving the visibility of tumors. Vergents lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all tumor tissue is removed. We are first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors. Our approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic-assisted surgical procedures.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access